Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Review Article

Metastatic gastric cancer treatment: a little slow but worthy progress

verfasst von: Ozkan Kanat, Bert H. O’Neil

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Metastatic gastric cancer is incurable and remains one of the leading causes of cancer-related deaths around the world. Despite the significant progress in its systemic treatment, metastatic gastric cancer is still a major therapeutic challenge for oncologists. Newer chemotherapy regimens and the addition of molecularly targeted agents to chemotherapy seem to provide better clinical outcomes for patients with metastatic gastric cancer. The objective of this article is to review the current treatment approach for this formidable disease.
Literatur
1.
2.
Yalcin S. Gastric cancer in Turkey-a bridge between West and East. Gastrointest Cancer Res. 2009;3:29–32.PubMed
3.
Wagner AD, Grothe W, Haerting J, Kleber G, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.PubMedCrossRef
4.
Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3:257–66.PubMedCrossRef
5.
Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008;13:794–806.PubMedCrossRef
6.
Price TJ, Shapiro JD, Segelov E, Karapetis CS. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol. 2012;6(2):199–209.PubMedCrossRef
7.
Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev. 2011;37:599–610.PubMedCrossRef
8.
Lee J, Lim T, Uhm JE, Park KW, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886–91.PubMedCrossRef
9.
Koo DH, Ryoo BY, Kim HJ, Ryu MH, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol. 2011;68:913–21.PubMedCrossRef
10.
Kim JG, Ryoo BY, Park YH, Kim BS, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:301–7.PubMedCrossRef
11.
Chau I, Norman AR, Cunningham D, Waters JS, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.PubMedCrossRef
12.
Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef
13.
Ohtsu A. Diverse eastern and Western approaches to the management of gastric cancer. Gastrointest Cancer Res. 2007;1(2 Suppl):S10–5.PubMed
14.
Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.PubMedCrossRef
15.
Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011;12:96–106.PubMedCrossRef
16.
Power DG, Kelsen DP, Shah MA. Advanced gastric cancer–slow but steady progress. Cancer Treat Rev. 2010;36:384–92.PubMedCrossRef
17.
Boku N, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol. 2008;13:196–200.PubMedCrossRef
18.
Boku N. Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol. 2011;41:1315–21.PubMedCrossRef
19.
Blum MA, Suzuki A, Taketa T, Ajani J. The role of S-1 in the treatment of gastric cancer. Gastrointest Cancer Targets Ther. 2011;1:59–67.
20.
21.
Boku N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol. 2008;13:483–7.PubMedCrossRef
22.
Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.PubMedCrossRef
23.
Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, et al. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer. 2003;39:1264–70.PubMedCrossRef
24.
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–20.PubMedCrossRef
25.
Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.PubMedCrossRef
26.
Koizumi W, Narahara H, Hara T, Takagane A, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef
27.
Boku N, Yamamoto S, Fukuda H, Shirao K, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.PubMedCrossRef
28.
Narahara H, Iishi H, Imamura H, Tsuburaya A, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14:72–80.PubMedCrossRef
29.
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.PubMedCrossRef
30.
Scartozzi M, Galizia E, Verdecchia L, Berardi R, et al. Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother. 2007;8:797–808.PubMedCrossRef
31.
Webb A, Cunningham D, Scarffe JH, Harper P, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.PubMed
32.
Miwa M, Ura M, Nishida M, Sawada N, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.PubMedCrossRef
33.
Cunningham D, Starling N, Rao S, Iveson T, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med. 2008;358:36–46.CrossRef
34.
Köhne CH, Catane R, Klein B, Ducreux M, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003;89:997–1001.PubMedCrossRef
35.
Moehler M, Eimermacher A, Siebler J, Höhler T, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92:2122–8.PubMedCrossRef
36.
Dank M, Zaluski J, Barone C, Valvere V, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–7.PubMedCrossRef
37.
Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12:132–41.PubMedCrossRef
38.
Ridwelski K, Gebauer T, Fahlke J, Kröning H, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47–51.PubMedCrossRef
39.
Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006;12:3402–7.PubMedCrossRef
40.
Chun JH, Kim HK, Lee JS, Choi JY, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol. 2005;28:188–94.PubMedCrossRef
41.
Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol. 2005;23:494–501.PubMedCrossRef
42.
Van Cutsem E, Van de Velde C, Roth A, Lordick F, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer. 2008;44:182–94.PubMedCrossRef
43.
Roth AD, Maibach R, Martinelli G, Fazio N, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol. 2000;11:301–6.PubMedCrossRef
44.
Roth AD, Fazio N, Stupp R, Falk S, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.PubMedCrossRef
45.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRef
46.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3210–6.PubMedCrossRef
47.
Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008;113:945–55.PubMedCrossRef
48.
Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol. 2011;18:e202–9.PubMedCrossRef
49.
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, et al. Gastric Cancer. J Natl Compr Canc Netw. 2010;8:378–409.PubMed
50.
Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658–63.PubMedCrossRef
51.
De Vita F, Giuliani F, Silvestris N, Catalano G, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010;36(suppl 3):S11–5.PubMedCrossRef
52.
Fornaro L, Lucchesi M, Caparello C, Vasile E, et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369–83.PubMedCrossRef
53.
Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001;8:151–9.PubMedCrossRef
54.
Barros FF, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology. 2010;56:560–72.PubMedCrossRef
55.
Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005;12(Suppl 1):S17–27.PubMedCrossRef
56.
Song HS, Do YR, Kim IH, Sohn SS, et al. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat. 2004;36:240–5.PubMedCrossRef
57.
Wong H, Yau T (2012) Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist (Epub ahead of print).
58.
Pinto C, Di Fabio F, Siena S, Cascinu S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:510–7.PubMedCrossRef
59.
Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G et al (2007) Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 25 (18S):4514 (Abstr).
60.
Han SW, Oh DY, Im SA, Park SR, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100:298–304.PubMedCrossRef
61.
Pinto C, Di Fabio F, Barone C, Siena S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261–8.PubMedCrossRef
62.
Zhang X, Xu J, Shen L, Wang J et al (2009) A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer [abstract LBA39]. Presented at the 2009 American Society of clinical Oncology Gastrointestinal Cancer Symposium, San Francisco, CA, 15–17 January 2009.
63.
Yeh K, Hsu C, Hsu C, Lin C, et al. Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. J Clin Oncol. 2009;27(15 suppl):4567.
64.
Woell E, Greil R, Eisterer W, Fridrik M et al (2008) Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) [abstract 15587]. Proc Am Soc Clin Oncol 26:662s.
65.
Moehler M, Mueller A, Trarbach T, Lordick F, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol. 2011;22:1358–66.PubMedCrossRef
66.
Kim C, Lee JL, Ryu MH, Chang HM, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs. 2011;29:366–73.PubMedCrossRef
67.
Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol. 2010;28(suppl 15):a4006.
68.
Richards DA, Kocs DM, Spira AI, McCollum AD et al (2011) Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomized phase II study. J Clin Oncol 29(suppl; abstr 4015).
69.
70.
Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D et al (2012) A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 30(suppl; abstr LBA4000).
71.
Sakai K, Mori S, Kawamoto T, Taniguchi S, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986;77:1047–52.PubMed
72.
Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol. 2011;19:506–8.PubMedCrossRef
73.
Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer. 2012;3:137–44.PubMedCrossRef
74.
Kaur A, Dasanu CA. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother. 2011;12:2493–503.PubMedCrossRef
75.
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.PubMedCrossRef
76.
Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther. 2011;4:21–6.PubMed
77.
Ngeow J, Tan IB, Choo SP. Targeted therapies in the treatment of gastric cancer. Asia Pac J Clin Oncol. 2011;7:224–35.PubMedCrossRef
78.
Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res. 2011;3:57–64.PubMedCrossRef
79.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMed
80.
Hofmann M, Stoss O, Shi D, Büttner R, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.PubMedCrossRef
81.
Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ (2011) Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 674182.
82.
Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer. Curr Opin Oncol. 2011;23:396–402.PubMedCrossRef
83.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
84.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.PubMedCrossRef
85.
Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19:329–37.PubMedCrossRef
86.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef
87.
Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev. 2006;25:373–85.PubMedCrossRef
88.
Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers–focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008;5:250–67.PubMedCrossRef
89.
Lieto E, Ferraraccio F, Orditura M, Castellano P, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69–79.PubMedCrossRef
90.
Maeda K, Chung YS, Ogawa Y, Takatsuka S, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858–63.PubMedCrossRef
91.
Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res. 1996;56:2671–6.PubMed
92.
Cortes-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol. 2009;11:349–55.PubMedCrossRef
93.
Shah MA, Ramanathan RK, Ilson DH, Levnor A, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201–6.PubMedCrossRef
94.
Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29:868–74.PubMedCrossRef
95.
Enzinger P, Ryan D, Regan E, Lehman N et al (2008) Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 26:4552Abstr.
96.
El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21:1999–2004.PubMedCrossRef
97.
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.PubMedCrossRef
98.
Shah M, Van Cutsem E, Kang Y, Dakhil SR et al (2012) Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. J Clin Oncol (Meeting Abstracts) 30:4(suppl 5).
99.
Van Cutsem E, Yeh KH, Bang YJ, Shen L et al (2012) Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 30(suppl 4):LBA3.
100.
Cappetta A, Lonardi S, Pastorelli D, Bergamo F, et al. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol. 2012;81:38–48.PubMed
Metadaten
Titel
Metastatic gastric cancer treatment: a little slow but worthy progress
verfasst von
Ozkan Kanat
Bert H. O’Neil
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0464-4

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Original Paper

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

Short Communication

Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study

Original Paper

Predictors and survival in patients with melanoma brain metastases

Original Paper

Junctional adhesion molecules 2 and 3 may potentially be involved in progression of gastric adenocarcinoma tumors

Original Paper

Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma

Original Paper

Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen